

Alchemia Announces Appointment of Non-Executive Chairman and Retirement of Non-Executive Chairman

Melbourne, Australia; 29 February 2016: Alchemia Limited, (ASX: ACL) a drug discovery and development company, today announced the appointment of Mr Simon Gennari to its Board as Non-Executive Chairman and the retirement of Mr. Ken Poutakidis as Non-Executive Chairman and member of the board.

Mr Gennari has over 20 years of experience in investment management, corporate finance and equity research in Europe and Australia. He is currently a principal of Dinimus Capital, an investment management and corporate advisory firm and serves on their investment committee. Previous roles include senior investment positions within a UK family office and global hedge fund. His extensive investment experience includes managing portfolios covering a diverse range of sectors and industries globally and within Australia including healthcare, industrials, technology, resources, agriculture, clean technology, retail and financial services. Within corporate finance his experience extends to mergers and acquisitions, capital markets, transaction structuring, strategy and valuation for listed and private enterprises including venture capital across debt and equity.

Alchemia Non-Executive Director, Nathan Drona, commented, *“We are delighted to welcome Simon to the Alchemia Board of Directors. His broad expertise in corporate finance, portfolio management, and advisory work will be of great importance for the company as we seek to identify a compelling path forward.”*

“In addition, The Board wishes to thank Mr Poutakidis for his contribution to Alchemia in helping the company successfully complete recent activities including the sale of its intellectual property rights to fondaparinux sodium to Dr. Reddy’s Laboratories (NYSE: RDY) and the subsequent return of capital to shareholders.”

Contacts

Alchemia Limited

Melanie Leydin
Chief Financial Officer
Tel: +61 3 9692 7222